Valeria Santini
Overview
Explore the profile of Valeria Santini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
192
Citations
4753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gisriel S, Aakash F, Bennett J, Hasserjian R, Loghavi S, DeZern A, et al.
Arch Pathol Lab Med
. 2025 Mar;
PMID: 40059041
Context.—: Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.—: To propose a standardized approach to MDS evaluation...
2.
Oliva E, Guo S, Lord-Bessen J, Yucel A, Latagliata R, Breccia M, et al.
Front Oncol
. 2025 Feb;
15:1507854.
PMID: 39990686
Background: Myelodysplastic neoplasms (MDS) are characterized by ineffective hematopoiesis, peripheral blood cytopenias, and an increased risk of progression to acute myeloid leukemia. One of the main treatment goals is improving...
3.
Gurnari C, Robin M, Ades L, Aljurf M, Almeida A, Duarte F, et al.
Blood
. 2025 Feb;
PMID: 39970324
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment...
4.
Consagra A, Lanino L, Al Ali N, Aguirre L, Xie Z, Chan O, et al.
Hemasphere
. 2025 Feb;
9(2):e70086.
PMID: 39944234
We explored the impact of luspatercept therapy on overall survival (OS) and possible predictors of response in low-risk (LR) myelodysplastic syndrome (MDS) patients. We evaluated 331 anemic patients treated with...
5.
Sekeres M, Santini V, Diez-Campelo M, Komrokji R, Fenaux P, Savona M, et al.
Leuk Lymphoma
. 2024 Nov;
66(3):529-534.
PMID: 39535901
No abstract available.
6.
Poloni A, Raaschou-Jensen K, Mohedo F, Paolini S, Oliva E, Buccisano F, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
25(3):e131-e142.
PMID: 39516085
Background: This noninterventional postauthorization safety study assessed the safety and effectiveness of lenalidomide in patients with transfusion-dependent, International Prognostic Scoring System (IPSS) Low- or Intermediate (Int)-1-risk myelodysplastic syndromes (MDS) associated...
7.
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, et al.
Lancet Haematol
. 2024 Oct;
11(11):e862-e872.
PMID: 39393368
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency...
8.
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, et al.
Mod Pathol
. 2024 Sep;
37(12):100615.
PMID: 39322118
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, 2 classification systems (the 5th edition of the World Health Organization...
9.
Geissler K, Koristek Z, Bernal Del Castillo T, Novak J, Rodriguez-Macias G, Metzelder S, et al.
Br J Haematol
. 2024 Sep;
205(5):1734-1745.
PMID: 39313917
This study compared decitabine exposure when administered IV (DEC-IV) at a dose of 20 mg/m for 5-days with orally administered decitabine with cedazuridine (DEC-C), as well as the clinical efficacy...
10.
Raddi M, Bencini S, Peruzzi B, Mattiuz G, De Pourcq S, Tanturli M, et al.
Blood Cancer J
. 2024 Aug;
14(1):127.
PMID: 39112451
No abstract available.